EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism

Hyunjoo Lee iD, Shabirul Haque iD, Rashmi Gupta, Jonathan E Kolitz, Steven L Allen iD, Kanti Rai, Nicholas Chiorazzi iD, Patricia K A Mongini iD

Lymphatics · 2024

DOI: 10.3390/lymphatics2020005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lymphatics, 2024. Verfasst von Hyunjoo Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY 11030, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAMS NIH HHS, Karches Family Foundation and NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CLL B cells express elevated pro-survival BCL2, and its selective inhibitor, venetoclax, significantly reduces leukemic cell load, leading to clinical remission. Nonetheless, relapses occur. This study evaluates the hypothesis that progressively diminished BCL2 protein in cycling CLL cells within patient lymph node niches contributes to relapse. Using CFSE-labeled, purified CLL populations known to respond with vigorous cycling in d6 cultures stimulated with TLR9-activating ODN (oligodeoxynucleotide) + IL15, we show that BCL2 protein progressively declines during consecutive cell divisions. In contrast, MCL1 and survivin are maintained/slightly elevated during cycling. Delayed pulsing of quiescent and activated CLL cultures with selective inhibitors of BCL2 or survivin revealed selective targeting of noncycling and cycling populations, respectively, raising implications for therapy. To address the hypothesis that BCL2-repressive miRs (miR15a/miR16-1), encoded in Chr13, are mechanistically involved, we compared BCL2 protein levels within ODN + IL15-stimulated CLL cells, with/without del(13q), yielding results suggesting these miRs contribute to BCL2 reduction. In support, within ODN-primed CLL cells, an IL15-driven STAT5/PI-3K pathway (required for vigorous cycling) triggers elevated p53 TF protein known to directly activate the miR15a/miR16-1 locus. Furthermore, IL15 signaling elicits the repression of BCL2 mRNA within 24 h. Additional comparisons of del(13q)+ and del(13q)−/− cohorts for elevated p53 TF expression during cycling suggest that a documented miR15a/miR16-1-mediated negative feedback loop for p53 synthesis is active during cycling. Findings that robust CLL cycling associates with progressively decreasing BCL2 protein that directly correlates with decreasing venetoclax susceptibility, combined with past findings that these cycling cells have the greatest potential for activation-induced cytosine deaminase (AICDA)-driven mutations, suggest that venetoclax treatment should be accompanied by modalities that selectively target the cycling compartment without eliciting further mutations. The employment of survivin inhibitors might be such an approach.

Schlagwörter

Stichwörter der Autor:innen

BCL2CLLYM155p53survivinvenetoclax

Autor:innen und Institutionen

  • The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY 11030, USA.
  • Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, USA.
  • Department of Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, USA.
  • Northwell Health Cancer Institute, Lake Success, NY 11042, USA.

ORCID-Profile: Hyunjoo Lee, Shabirul Haque, Steven L Allen, Nicholas Chiorazzi, Patricia K A Mongini

Förderung

  • NCI NIH HHS
  • NIAMS NIH HHS
  • Karches Family Foundation and NIH

Zitieren

APA

Lee, H., Haque, S., Gupta, R., Kolitz, J. E., Allen, S. L., Rai, K., Chiorazzi, N., & Mongini, P. K. A. (2024). BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism. Lymphatics. https://doi.org/10.3390/lymphatics2020005

Vancouver

Lee H, Haque S, Gupta R, Kolitz JE, Allen SL, Rai K, et al. BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism. Lymphatics. 2024. doi:10.3390/lymphatics2020005

BibTeX
@article{Lee2024,
  author = {Lee, Hyunjoo and Haque, Shabirul and Gupta, Rashmi and Kolitz, Jonathan E and Allen, Steven L and Rai, Kanti and Chiorazzi, Nicholas and Mongini, Patricia K A},
  title = {BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism},
  journal = {Lymphatics},
  year = {2024},
  doi = {10.3390/lymphatics2020005}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche